These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 22826888)

  • 41. Hyaluronan-based dissolving microneedles with high antigen content for intradermal vaccination: Formulation, physicochemical characterization and immunogenicity assessment.
    Leone M; Priester MI; Romeijn S; Nejadnik MR; Mönkäre J; O'Mahony C; Jiskoot W; Kersten G; Bouwstra JA
    Eur J Pharm Biopharm; 2019 Jan; 134():49-59. PubMed ID: 30453025
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biocompatible Mater Constructed Microneedle Arrays as a Novel Vaccine Adjuvant- Delivery System for Cutaneous and Mucosal Vaccination.
    Wang T; Wang N
    Curr Pharm Des; 2015; 21(36):5245-55. PubMed ID: 26412356
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Old and new prescriptions for infectious diseases and the newest recipes for biomedical products in plants].
    Koprowski H
    Arch Immunol Ther Exp (Warsz); 2002; 50(6):365-9. PubMed ID: 12549429
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New approaches for antigen discovery, production and delivery: vaccines for veterinary and human use.
    Potter AA; Babiuk LA
    Curr Drug Targets Infect Disord; 2001 Nov; 1(3):249-62. PubMed ID: 12455399
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Controlled and targeted release of antigens by intelligent shell for improving applicability of oral vaccines.
    Zhang L; Zeng Z; Hu C; Bellis SL; Yang W; Su Y; Zhang X; Wu Y
    Biomaterials; 2016 Jan; 77():307-19. PubMed ID: 26624805
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A strategic approach to vaccine development: animal models, monitoring vaccine efficacy, formulation and delivery.
    Griffin JF
    Adv Drug Deliv Rev; 2002 Oct; 54(6):851-61. PubMed ID: 12363434
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunomodulators and delivery systems for vaccination by mucosal routes.
    Ryan EJ; Daly LM; Mills KH
    Trends Biotechnol; 2001 Aug; 19(8):293-304. PubMed ID: 11451471
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enhancing vaccine effectiveness with delivery technology.
    Beitelshees M; Li Y; Pfeifer BA
    Curr Opin Biotechnol; 2016 Dec; 42():24-29. PubMed ID: 26954947
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization.
    Chen X; Fernando GJ; Crichton ML; Flaim C; Yukiko SR; Fairmaid EJ; Corbett HJ; Primiero CA; Ansaldo AB; Frazer IH; Brown LE; Kendall MA
    J Control Release; 2011 Jun; 152(3):349-55. PubMed ID: 21371510
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Stimulation of local antibody production: parenteral or mucosal vaccination?
    Bouvet JP; Decroix N; Pamonsinlapatham P
    Trends Immunol; 2002 Apr; 23(4):209-13. PubMed ID: 11923116
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Challenges of vaccine presentation and delivery: How can we design vaccines to have optimal programmatic impact?
    Giersing BK; Kahn AL; Jarrahian C; Mvundura M; Rodriguez C; Okayasu H; Zehrung D
    Vaccine; 2017 Dec; 35(49 Pt A):6793-6797. PubMed ID: 28566254
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Controlled delivery of antigens and adjuvants in vaccine development.
    Zhao Z; Leong KW
    J Pharm Sci; 1996 Dec; 85(12):1261-70. PubMed ID: 8961136
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rational design of nasal vaccines.
    Slütter B; Hagenaars N; Jiskoot W
    J Drug Target; 2008 Jan; 16(1):1-17. PubMed ID: 18172815
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of vaccine delivery vehicles based on lactic acid bacteria.
    Tarahomjoo S
    Mol Biotechnol; 2012 Jun; 51(2):183-99. PubMed ID: 21901278
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antigen delivery to mucosa-associated lymphoid tissues using liposomes as a carrier.
    Zho F; Neutra MR
    Biosci Rep; 2002 Apr; 22(2):355-69. PubMed ID: 12428910
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current state and challenges in developing oral vaccines.
    Vela Ramirez JE; Sharpe LA; Peppas NA
    Adv Drug Deliv Rev; 2017 May; 114():116-131. PubMed ID: 28438674
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Animal vaccines based on orally presented yeast recombinants.
    Shin MK; Yoo HS
    Vaccine; 2013 Sep; 31(40):4287-92. PubMed ID: 23891501
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pulmonary vaccine delivery.
    Lu D; Hickey AJ
    Expert Rev Vaccines; 2007 Apr; 6(2):213-26. PubMed ID: 17408371
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting vaccines to dendritic cells.
    Foged C; Sundblad A; Hovgaard L
    Pharm Res; 2002 Mar; 19(3):229-38. PubMed ID: 11934227
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Oral vaccination and vaccine-entrapped microparticle delivery system].
    Li FQ; Fei YB; Su H; Hu JH
    Yao Xue Xue Bao; 2007 Mar; 42(3):245-51. PubMed ID: 17520821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.